Catalyst Biosciences Announces Oral and Poster Presentations at the 13th Annual EAHAD Congress

SOUTH SAN FRANCISCO, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Catalyst Biosciences, Inc. (NASDAQ: CBIO), today announced one oral and three poster presentations at the 13th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) being held in The Hague, Netherlands on February 5 - 7, 2020.  Johnny Mahlangu, M.B. B.Ch., M.Med., F.C.Path., Professor of haematology, faculty of health sciences, head of the School of Pathology at the University of Witwatersrand in Johannesburg, South Africa, and a principal investigator in the Dalcinonacog Alfa (DalcA) Phase 2b clinical trial will deliver the oral presentation.

Click to view original post